Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: Current challenges and future applications

Haematologica

Volumn 98, Issue 1, 2013, Pages 7-9

  Efficace, Fabio ^a   Lo Coco, Francesco ^b,c  

^a Data Center   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PATIENT; EDITORIAL; HEALTH STATUS; HUMAN; OUTCOME ASSESSMENT; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SURVIVAL PREDICTION;

FEMALE; GERIATRIC ASSESSMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE;

EID: 84872063790     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.078501     Document Type: Editorial

References (14)

1. US Food and Drug Administration: Guidance for Industry. Patientreported outcome measures: Use in medical product development to support labeling claims. US. Department of Health and Human Services Food and Drug Administration December, 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM193282.pdf
2. Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2012 Aug 8; [Epub ahead of print].
3. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26(8):1355-63.
4. Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, et al. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2008;26(12):2020-6.
5. Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica. 2011;96(5):696-702
6. Efficace F, Cartoni C, Niscola P, Tendas A, Meloni E, Scaramucci L, et al. Predicting survival in advanced hematologic malignancies: do patient-reported symptoms matter? Eur J Haematol. 2012;89(5):410-6.
7. Strasser-Weippl K, Ludwig H. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur J Haematol. 2008;81(5):374-9
8. Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M, et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol. 2006;24(6):976-82
9. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol. 2001;18(1):85-94.
10. Wisløff F, Hjorth M. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1997;97(1):29-37.
11. Mauer M, Bottomley A, Coens C, Gotay C. Prognostic factor analysis of health-related quality of life data in cancer: a statistical methodological evaluation. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):179-96.
12. Van Steen K, Curran D, Kramer J, Molenberghs G, Van Vreckem A, Bottomley A, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med. 2002;21(24):3865-84.
13. Bottomley A, Coens C, Efficace F, Gaafar R, Manegold C, Burgers S, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol. 2007;25(36):5770-6.
14. Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17(11):1698-704.